Background: CRF2 is a receptor for corticotropin releasing factor. Shows high-affinity CRF binding. Also binds to urocortin I, II and III. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase. Expression levels shown to be comparable in adipose tissues and the heart of humans. Expression in adipose tissues suggests a functional role for CRH in human fat.
Immunogen: Synthetic peptide derived from the N-terminal region of the CRF2R protein.
Purification Method: Ammonium Sulfate Precipitation.
Formulation: Provided as solution in phosphate buffered saline with 0.08% sodium azide.
References: 1. Liaw, C.W., et al. 'Cloning and characterization of the human corticotropin-releasing factor-2 receptor complementary deoxyribonucleic acid.' Endocrinology 1996, 137, 72-77.
2. Isfort, R.J., et al. 'Discovery of corticotropin releasing factor 2 receptor selective sauvagine analogues for treatment of skeletal muscle atrophy.' J. Med. Chem. 2005, 48, 262-265.
3. Argiles, J.M., et al. 'Effects of CRF2R agonist on tumor growth and cachexia in mice implanted with Lewis lung carcinoma cells.' Muscle Nerve 2008, 37, 190-195.
4. Tao, J., et al. 'Activation of corticotropin-releasing factor 2 receptor inhibits Purkinje neuron P-type calcium currents via G(o)alpha-dependent PKC epsilon pathway.' Cell Signal 2009, 21, 1436-1443.
5. Seres, J., et al. 'Corticotropin-releasing hormone system in human adipose tissue.' J. Clin. Endocrin. & Metab. 2004, 89, 965-970.
UniProt: Q13324.
Caution: This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals.
English
Deutsch
